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Objectives We sought to analyze outcomes of patients with degenerated surgically implanted bio-
prosthetic heart valves undergoing valve-in-valve (viv) transcatheter aortic valve implantation (TAVI).
Background Redo cardiac surgery for degenerated bioprosthetic heart valves is associated with in-
creased risks, particular in elderly patients with comorbidities. For these patients, TAVI may be an
attractive, less invasive treatment option.
Methods Data from 47 patients age 64 to 97 years (logistic euroSCORE: 35.0  18.5%) undergoing
transfemoral (n  25) or transapical (n  22) viv-TAVI for failed bioprosthetic aortic valves 113  65
months after initial surgery at 9 clinical sites in Germany and Switzerland were analyzed.
Results Valve-in-valve TAVI was technically successful in all patients, with 2 patients requiring bail-
out implantation of a second TAVI prosthesis for severe regurgitation during the procedure. There
was 1 procedural death as the result of low-output failure. Valvular function after viv-TAVI was ex-
cellent with respect to valve competence, but increased transvalvular gradients 20 mm Hg were
noted in 44% of patients. Vascular access complications occurred in 6 (13%) patients, and 5 (11%)
patients required new pacemaker implantation after viv-TAVI. Renal failure requiring dialysis oc-
curred in 4 (9%) patients. Mortality at 30 days was 17% (1 procedural and 7 post-procedural deaths),
with 3 of 8 fatalities the result of non–valve-related septic complications.
Conclusions Valve-in-valve TAVI can be performed with high technical success rates, acceptable
post-procedural valvular function, and excellent functional improvement. However, in these predom-
inantly elderly high-risk patients with multiple comorbidities, viv-TAVI was associated with 17% mor-
tality, often because of septic complications arising in the post-operative phase. (J Am Coll Cardiol
Intv 2011;4:1218–27) © 2011 by the American College of Cardiology Foundation
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1219Transcatheter aortic valve implantation (TAVI) has emerged
to become an attractive, less invasive treatment option for
patients with symptomatic severe aortic valve stenosis (1,2).
Currently, patients deemed at excessive risk for conventional
surgical valve replacement are considered candidates for TAVI
(3). These patients are typically elderly patients with significant
omorbidities, usually reflected by a logistic euroSCORE of
20% or a Society of Thoracic Surgeons (STS) risk of
ortality of 10% for perioperative mortality (4). Patients
ith other factors that increase surgical risk but that are not
aptured by these scoring systems (e.g., general frailty, porce-
ain aorta, prior chest radiation, or cardiac surgery) are also
eemed appropriate candidates for TAVI (5,6). In particular,
atients with degeneration of previously surgically implanted
issue heart valves may potentially benefit from beating-heart
AVI, obviating the risks associated with using cardioplegia
nd cardiopulmonary bypass during redo surgery (7).
Previous animal studies and selected case series have
uggested that valve-in-valve (viv) TAVI for degenerated
urgical bioprostheses is technically feasible and safe (8–15).
owever, the small number of patients undergoing viv-
AVI reported so far even at pioneering centers precludes
eliable insights into the clinical success and complication
ates of viv-TAVI (11,12,14). The major goal of this study
as to provide insights into the technical success and
utcomes in patients undergoing viv-TAVI in contempo-
ary practice across several clinical sites in Germany and
witzerland.
ethods
Registry design. The present independent registry on viv-
TAVI was founded by an interdisciplinary group of TAVI
experts (H.E., U.S., H.T., H.B., P.K., M.T., T.W.). The
rarity of patients undergoing viv-TAVI at the present time
precludes larger numbers of cases with this particular TAVI
indication even at a very large tertiary care single center. Our
registry was designed to collect data on this specific TAVI
indication across several referral sites to accumulate a
maximum of information on a larger number of cases with
this otherwise rare condition with the hope of providing
extended insights into clinical success and complication
rates. The registry was approved by the ethics committee of
the University of Duisburg–Essen. There was no funding by
the industry.
Collection of patient data. A case report form with 55
ariables, including demographics, history, procedural char-
cteristics, and outcomes of patients, was developed by a
ore group and agreed upon by the participating sites.
atients who underwent viv-TAVI were identified from the
ocal TAVI database at the individual institution. Patient
ata were retrospectively collected by physician review of
ospital charts and entered into a paper case report form
hat was faxed or e-mailed to the coordinating site at the dniversity of Duisburg–Essen in Essen, Germany. Case
eport forms were reviewed for clinical face validity and
nalytical internal validity by the lead author (H.E.). All
nconsistencies were resolved by contacting the local inves-
igators. On-site monitoring for data validation was not
erformed. All data were manually entered into a Microsoft
xcel database for further analysis.
Viv-TAVI procedure. Valve-in-valve TAVI was performed
ither transapically or transfemorally, as previously de-
cribed (16–18). The balloon-expandable, trileaflet bovine
tent valve (Edwards Sapien, and later, Edwards Sapien XT,
dwards Lifesciences, Irvine, California) was available for
oth transapical and transfemoral TAVI, whereas the self-
xpandable, trileaflet porcine pericardial tissue stent-valve
Medtronic CoreValve Revalving System, Minneapolis,
innesota) was available only for retrograde transfemoral or
rans-subclavian access.
Transapical viv-TAVI was performed using a left anterolat-
ral minithoracotomy in the fifth or sixth intercostal space.
fter placement of left ventricular apical purse-string sutures
nd puncture of the left ventricle,
standard guidewire was ad-
anced across the aortic arch
own to the descending aorta us-
ng a Judkins right coronary cath-
ter and exchanged for a stiff
uidewire. Balloon valvuloplasty
f the degenerated surgical bio-
rosthesis was left at the discre-
ion of the operator and was
erformed only in case of ste-
otic physiology. Angiographic
maging was aligned in a per-
endicular plane with the wire
rame of the degenerated bioprosthesis. A crimped Edwards
apien valve was advanced into the bioprosthesis and
ositioned under angiographic guidance. Finally, the valve
as implanted under rapid right ventricular pacing to mini-
ize movement (Fig. 1). After angiographic confirmation of
table and successful implant position, the sheath was
etrieved and the left ventricular apex was closed as previ-
usly described (18).
For transfemoral viv-TAVI, either percutaneous or sur-
ical access to the left or right common femoral artery was
btained. For percutaneous procedures, vascular closure
evices (Prostar or Perclose Proglide, Abbott Vascular,
bbott Park, Illinois) were used in a pre-close technique
19). The degenerated bioprosthesis was crossed, usually
sing an Amplatz left coronary catheter, and a stiff guide-
ire was placed deep into the apex of the left ventricle.
alloon valvuloplasty of the degenerated surgical biopros-
hesis before valve implantation was left at the discretion of
he operator. After insertion of an 18- to 24-F sheath, the
Abbreviations
and Acronyms
CAD  coronary artery
disease
NYHA  New York Heart
Association
STS  Society of Thoracic
Surgeons
TAVI  transcatheter aortic
valve implantation
TEE  transesophageal
echocardiography
viv  valve-in-valveelivery system containing the crimped TAVI valve was
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1220advanced into the degenerated bioprosthesis. After posi-
tioning using fluoroscopic and angiographic and/or echo-
cardiographic guidance, the balloon-expandable stent valve
was deployed by balloon inflation under rapid right ventric-
ular pacing at 160 to 220 beats/min (Fig. 2), whereas the
self-expandable prosthesis was deployed stepwise and under
guidance by several small-volume angiograms with and
without accelerated pacing (110 to 130 beats/min) (Fig. 3).
After confirmation of the correct position of the valve, the
introducer sheath was withdrawn, and access closure was
performed according to the local institutional protocol.
Figure 1. Post-Procedural Result of TA Viv-TAVI Using the
Balloon-Expandable Edwards Sapien Valve
Viv-TAVI was performed for a failed Carpentier Edwards bioprosthesis.
TA  transapical; TAVI  transcatheter aortic valve implantation;
Viv  valve-in-valve.
Figure 2. Transfemoral Viv-TAVI Using the Balloon-Expandable Edwards Sa
Viv-TAVI was performed in a patient with a failed Carpentier Edwards Perimou
(A–C). Abbreviations as in Figure 1.Statistical analysis. Categorical data are presented as frequen-
cies; continuous variables are expressed as mean  SD or
median and range. Comparisons between groups were made
with the chi-square or Fisher exact test (when cell count was
5) for categorical variables and the 2-sided Student t test for
continuous variables. Multiple testing analysis was performed
using ANOVA using the Bonferroni correction for post hoc
analysis. Estimates of unadjusted overall survival were deter-
mined using the Kaplan-Meier nonparametric method. A p
value of 0.05 was considered statistically significant. All
T Valve
prosthesis (Edwards Lifesciences) and with severe valvular regurgitation
Figure 3. Post-Procedural Result of TF Viv-TAVI Using the
Self-Expandable Medtronic CoreValve Revalving System
Viv-TAVI was performed for a failed Mitroﬂow bioprosthesis (Sorin Group,
Milan, Italy). TF  transfemoral; other abbreviations as in Figure 1 (Online
Video 1).pien X
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1221statistical analyses were performed using the SPSS software
package (version 17.0, SPSS, Chicago, Illinois).
Results
Between 2005 and November 2010, a total of 1,545 TAVI
procedures were performed at the participating centers.
Among these, 47 (3%) patients underwent viv-TAVI for
degenerated bioprostheses.
Patient demographics. Patient demographics are summarized
in Table 1. Mean age of the patients was 80.3 7.1 years, with
most patients (60%) being males. The logistic euroSCORE
ranged between 8.5% and 88.9%, with a mean of 35.0% 
18.5%. Almost all patients were severely symptomatic, with 45
of 47 (96%) patients in New York Heart Association (NYHA)
functional class III before TAVI.
Degenerated bioprosthetic heart valves. Tissue valve failure
ffected 47 aortic surgical bioprostheses (Table 2); a single
atient underwent simultaneous viv-TAVI for degenerated
ortic and mitral bioprostheses. Indications for viv-TAVI
ncluded isolated xenograft stenosis in 22 (47%) patients,
solated severe regurgitation of the bioprosthesis in 15 (32%)
atients, and mixed stenosis and regurgitation in the remaining
0 (21%) patients. At baseline, the mean gradient across the
ioprosthesis was 38  15 mm Hg, and the valve orifice area
as 0.90  0.42 cm2. Bioprostheses had been implanted
urgically 113  65 (9 to 261) months before viv-TAVI.
Procedural data. Twenty-two (47%) patients underwent
ransapical viv-TAVI, whereas the remaining 25 (53%) were
reated transfemorally (Table 3). The logistic euroSCOREs
f patients undergoing transapical procedures were not signif-
Table 1. Patient Demographics (N  47)
Age, yrs 79.8 7.1 (63–97)
Females 19 (40%)
CAD 28 (60%)
Previous myocardial infarction 12 (26%)
Previous CABG 16 (34%)
Previous PCI 8 (17%)
Diabetes mellitus 13 (28%)
Chronic renal failure 28 (60%)
Requiring dialysis 4 (9%)
Creatinine at baseline, mg/dl 1.7 1.2 (0.6–6.9)
Logistic EuroSCORE, % 35.0 18.5 (8.5–88.9)
STS score, % 11.6 8.5 (2.2–34.9)
NYHA functional class before TAVI
Class I 0
Class II 2 (4%)
Class III 39 (83%)
Class IV 6 (13%)
Left ventricular ejection fraction, % 52 12 (17–70)
Values are mean SD (range) or n (%).
CABG  coronary artery bypass graft surgery; CAD  coronary artery disease; NYHA  New
York Heart Association; PCI  percutaneous coronary intervention; STS  Society of ThoracicSurgeons; TAVI transcatheter aortic valve implantation.cantly higher than in those patients treated transfemorally
38.8  19.2% vs. 31.6  17.5%, p  0.185). The Edwards
Sapien prosthesis was used in 75% of patients, with the
remaining undergoing viv-TAVI with the Medtronic Cor-
eValve valve (Figs. 1, 2, and 3). General anesthesia was used in
17 (36%) patients (all transfemoral TAVI).
In all patients, at least 1 stent valve was successfully
implanted into the failed surgical bioprosthesis. Implanta-
tion height of TAVI prosthesis within the bioprosthesis was
judged as “ideal” by the operator in 92% of patients, but 4
(8%) were judged as being implanted too low. After im-
plantation, the mean transvalvular gradient was significantly
reduced to 17  10 mm Hg, whereas the aortic valve area
as increased to 1.61  0.47 cm2 (p  0.001 vs. baseline)
(Table 3). However, 15 (44%) of 34 patients with available
data on transvalvular gradients after viv-TAVI had increased
mean transvalvular gradients20 mm Hg (Table 4). Patients
with increased transvalvular gradients 20 mm Hg after
viv-TAVI had smaller surgical bioprosthetic diameters as
compared with patients with lower final gradients (22.3 
1.2 mm vs. 23.7  2.0 mm, p  0.029). Conversely, it
appeared that patients with small surgical bioprostheses had
higher final transvalvular gradients after viv-TAVI (21 mm:
19.9  10.2 mm Hg; 23 mm: 18.5  8.4 mm Hg) than
those with greater bioprostheses (25 mm: 8.9  8.2 mm
Hg, p  0.035 vs. 21 mm; p  0.048 vs. 23 mm). The
relation of the TAVI prosthesis diameter to the diameter of
the surgical bioprostheses (“prosthesis-to-prosthesis match”
[20]) was, however, not different between patients with and
without elevated transvalvular gradients (1.06  0.07 vs.
Table 2. Bioprosthetic Heart Valve Data (N  47)
Position of the treated bioprosthesis
Aortic 47 (100%)*
Type of surgical bioprosthesis
Stented valve 45 (96%)
Stentless aortic root valve 2 (4%)
Diameter of surgical bioprosthesis,† mm 23
Time since valve replacement surgery, months 113 65 (9–261)
Mean transbioprosthetic gradient before TAVI, mm Hg 38 15 (9–73)
Valve oriﬁce area (cm2) 0.90 0.42 (0.40–2.50)
Regurgitation across bioprosthesis before TAVI
None 11 (23%)
Mild 11 (23%)
Moderate 7 (15%)
Severe 18 (38%)
Mode of failure of the bioprosthesis prompting TAVI
Stenosis 22 (47%)
Regurgitation 15 (32%)
Mixed stenotic/regurgitation 10 (21%)
Values are n (%), median, or mean  SD (range). *A single patient received simultaneous
valve-in-valve transcatheter aortic valve implantation (TAVI) of aortic and mitral bioprostheses.
†According to the manufacturer.1.02  0.02, p  0.254).
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1222With respect to valve competence, none or only mild
regurgitation was observed in 46 of the 47 patients (98%) at
the end of the procedure, with no case of moderate or
severe regurgitation (Fig. 4). During the procedure, how-
ever, severe regurgitation occurred in 2 patients, requiring
bail-out implantation of a second TAVI prosthesis during the
same index procedure: In 1 male patient, severe central regur-
gitation was observed after transapical implantation of an
Edwards Sapien valve, requiring implantation of another Ed-
wards Sapien valve (“valve-in-valve-in-valve”). In the second
patient, implantation of a 29-mm Medtronic CoreValve pros-
thesis resulted in too low a position with severe paravalvular
regurgitation. Therefore, a second Medtronic CoreValve pros-
thesis was implanted with good result.
A single patient died during the procedure as a result of
refractory low-output cardiac failure (Table 3). Procedural
complications occurred in 9 (19%) patients and predomi-
nantly concerned vascular access complications in 6 of these
9 patients (Table 4).
Post-procedural outcome. After TAVI, patients were stabi-
ized at the intensive care unit for a median of 2 days (Table 5).
uring the in-hospital period, 16 (34%) patients developed
dditional complications, such as renal failure requiring dialysis
Table 3. Procedural Data (N  47)
Prosthesis used for viv-TAVI
Edwards Sapien 35 (75%)
23 mm 29
26 mm 6
Medtronic CoreValve Revalving System 12 (25%)
26 mm 11
29 mm 1
Approach
Transapical 22 (47%)
Transfemoral 25 (53%)
General anesthesia 17 (36%)
Use of intraprocedural TEE 31 (66%)
Valvuloplasty before TAVI 24 (51%)
Procedural success 46 (98%)
Implantation height*
Ideal 43 (92%)
Too low 4 (9%)
Balloon dilation after TAVI 1 (2%)
Mean gradient after TAVI, mm Hg 17 10 (3–35)
Valve oriﬁce area after TAVI, cm2 1.61 0.48 (0.90–3.20)
Regurgitation after TAVI
None 26 (55%)
Mild 20 (43%)
Moderate 1 (2%)
Severe 0
Values are n (%), n, or mean SD (range). *as judged by the operator.
TAVI  transcatheter aortic valve implantation; TEE  transesophageal echocardiography;
viv valve-in-valve.n 4 (9%) patients. New permanent pacemaker implantationas performed in 5 (11%) patients. The rate of new pacemaker
mplantation was nonsignificantly higher in patients undergo-
ng Medtronic CoreValve implantation compared with those
ndergoing implantation of an Edwards Sapien valve (33% vs.
%, p  0.109). Other complications included low-output
ardiac failure (n  3), infectious complications (e.g., pneu-
onia, n  3), or bleeding at the transapical access site
equiring surgical revision (n  1). The all-cause 30-day
ortality rate was 17% (1 procedural and an additional 7
n-hospital deaths). Deaths were related to cardiac causes in 5
atients (low-output cardiac failure in 4, arrhythmia in 1).
eath in the 3 remaining patients was related to sepsis arising
uring the post-operative phase.
Survivors versus nonsurvivors. Nonsurvivors were signifi-
antly older, had higher logistic euroSCOREs and STS
cores, and had decreased left ventricular function than
hose surviving the in-hospital period (Table 6). Five of the
deaths occurred during the early experience (first half of
he patients). Thirty-day mortality in patients undergoing
ransfemoral TAVI was nonsignificantly lower than in
atients undergoing transapical TAVI (12% vs. 22.7%, p 
.446). Interestingly, mortality rates were higher among pa-
ients with coronary artery disease (CAD) than among those
ithout CAD (21.4% vs. 5.6%, p  0.031), among patients
ith previous coronary intervention (37.5% vs. 10.8%, p 
.085), and patients in chronic renal failure at baseline (75% vs.
%, p  0.018). The small number of patients and events,
owever, precluded any meaningful multivariate analysis.
Follow-up. Forty patients were finally discharged after a
median in-hospital stay of 8 days. Patients surviving the
in-hospital period showed significant symptom relief after
TAVI, with only a single (2%) patient remaining in NYHA
functional class III compared with baseline when most
patients (45 of 47 [96%]) were in NYHA functional class
III (p  0.01) (Fig. 5). Figure 6 shows the Kaplan-Meier
urvival curve of patients undergoing viv-TAVI.
iscussion
The present registry comprises the largest experience with
viv-TAVI for degenerated aortic bioprostheses reported so far.
Our results were obtained in a “real-world” environment and
confirm the feasibility of both the transfemoral and transapical
approaches for the treatment of failed aortic bioprostheses
observed in previous studies (11,12,14). Valve-in-valve TAVI
resulted in a significant improvement of symptom status in
almost all patients. Valvular function after viv-TAVI was
excellent with respect to valve competence; however, elevated
transvalvular gradients 20 mm Hg were observed in 44% of
patients, particularly in those with degenerated surgical bio-
prostheses of small diameters. In the present series of high-risk
patients for redo surgery, with a mean age of 80 years and a
mean logistic euroSCORE of 35.0%, viv-TAVI was associated
with incident risks of major complications and death. Overall
e Medic
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122330-day mortality was 17%, with 5 of the 8 patients dying
within the first 30 days of being treated transapically. Three of
the 8 fatalities were related to post-operative infectious or
septic complications, perhaps a reflection of the severely re-
duced general health status of these frail elderly patients and
associated inadequacies (resulting from a paucity of data) in
post-TAVI care of these patients. These elderly comorbid
patients were also prone to distinct complications that occurred
in every third patient during the in-hospital period.
Bioprosthetic heart valves reduce the risks associated with
lifelong oral anticoagulation and are therefore often favored
over mechanical valves, particularly in elderly patients un-
dergoing conventional valve replacement surgery (7,8).
With time, however, this advantage is offset by degeneration
Table 4. Individual Surgical Bioprosthesis Data and Hemodynamic Results
Surgical
Bioprosthesis
Labeled
Size
Mode of
Bioprosthesis
Failure
Implanted
TAVI
Prosthesis
Transvalvula
at Bas
(mm
CE Perimount 21 mm Stenosis ES 23 mm 47
Stenosis ES 23 mm 45
Mixed ES 23 mm 48
CE Perimount 23 mm Stenosis ES 26 mm 55
CE Perimount 25 mm Insufﬁciency ES 26 mm 28
Insufﬁciency ES 26 mm 16
Mixed ES 26 mm 44
CE Perimount Magna 25 mm Insufﬁciency ES 23 mm 25
CE Porcine 23 mm Stenosis ES 23 mm 27
CE Porcine 27 mm Insufﬁciency ES 23 mm 9
MDT Hancock II 21 mm Insufﬁciency CV 26 mm 15
MDT Hancock II 23 mm Mixed ES 23 mm 54
Stenosis ES 23 mm 26
Stenosis ES 23 mm 53
Stenosis ES 23 mm 31
Insufﬁciency ES 23 mm 27
Stenosis ES 23 mm 55
MDT Hancock II 25 mm Insufﬁciency ES 23 mm 11
MDT Mosaic 21 mm Insufﬁciency CV 26 mm 20
MDT Mosaic 23 mm Insufﬁciency ES 23 mm 29
MDT Mosaic Ultra 25 mm Stenosis ES 23 mm 32
SJM Biocor 23 mm Stenosis ES 23 mm 32
Insufﬁciency CV 26 mm 44
SJM Biocor 25 mm Insufﬁciency ES 23 mm 44
SJM Epic 23 mm Stenosis ES 23 mm 49
Sorin Mitroﬂow 21 mm Mixed ES 23 mm 56
Mixed ES 23 mm 53
Stenosis ES 23 mm 35
Mixed CV 26 mm 73
Sorin Mitroﬂow 23 mm Stenosis ES 23 mm 42
Insufﬁciency ES 23 mm 12
Stenosis ES 23 mm 45
Stenosis ES 23 mm 45
CE Carpentier Edwards; CV CoreValve; ES Edwards Sapien; MDTMedtronic; SJM St. Judof the bioprosthetic valve tissue, eventually resulting infailure of the tissue valve with either severe stenosis or
valvular incompetence. Reoperation has been the standard
treatment for failed tissue heart valves, but this exposes the
patient to the risks associated with redo cardiac surgery. In
patients with mean ages ranging from 56 to 64 years, the
risk of death for redo surgery has been estimated to be 3.8%
to 5.2% (21–23). However, bioprosthesis failure usually
occurs several years after initial surgery, and the risk of redo
surgery may thus be further increased as patients have
become older and more comorbid in the meantime. Previ-
ous animal studies as well as selected patient series have
supported the feasibility and/or safety of using viv-TAVI for
failed bioprosthetic aortic valves (8,11,12,14). The series of
Kempfert et al. (12) as well as the series from Webb et al.
Viv-TAVI
ient Transvalvular Gradient
After Viv-TAVI
(mm Hg)
Aortic Regurgitation
at Baseline
(Grade 0–3)
Aortic Regurgitation
After Viv-TAVI
(Grade 0–3)
21 0 0
8 0 0
32 3 1
24 0 1
7 3 1
30 3 0
8 3 1
6 3 0
12 1 0
3 3 0
10 3 2
35 2 0
12 0 0
18 1 0
7 1 0
20 3 1
35 0 0
5 2 0
5 3 0
25 3 0
11 0 0
25 0 0
14 2 1
6 2 1
29 0 0
30 3 1
18 3 1
20 1 1
20 2 0
11 0 1
5 3 0
20 1 0
20 1 0
al; other abbreviations as in Table 3.After
r Grad
eline
Hg)(11) have demonstrated that these elderly patients (mean
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1224age 78 and 82 years, respectively) may even undergo
viv-TAVI without mortality, although these series probably
represented small numbers of highly selected cases from expert
institutions.
Our data extend the findings of these previous reports, sup-
porting the feasibility and high success rates for viv-TAVI for
bioprosthetic valve failure in “real-world” clinical practice. In our
multicenter experience, viv-TAVI was, however, associated with a
30-day mortality of 17% (8 of 47 patients), an observation that
merits some further discussion. Given that patients were quite old
(mean age: 80.3 years) with a high rate of comorbid conditions
and predicted mean 30-day mortality based on a logistic euro-
SCORE of 35%, this mortality rate appears at the very least to be
comparable (perhaps somewhat better) with that expected with
redo valve replacement in this cohort. Nonetheless, mortality in
the present series was somewhat higher than that observed in the
series by Webb et al. (11) and Kempfert et al. (12). Although the
lower mortality in these 2 small series may be a play of chance, it
is also likely that inexperienced operators with lower volume and
a different patient case mix than in the present registry originating
from sites involved in pioneering the TAVI technique and with
experienced, large-volume operators may have accounted for at
least some of the differences in the mortality between our registry
and the 2 case series mentioned in the previous text (11,12).
Additionally, it should be noted that 5 of 8 patients who died the
first 30 days underwent transapical viv-TAVI. Our results also
Figure 4. Valvular Competence Before and After Viv-TAVI
Abbreviations as in Figure 1.suggest that improvements of post-operative patient care mayhave significant impact on outcomes after viv-TAVI. Three of the
8 fatalities were in fact related to septic complications (e.g.,
pneumonia) arising only in the post-operative course, highlighting
the difficulties of managing these elderly and fragile patients after
a technically successful viv-TAVI procedure.
Valve function after viv-TAVI intuitively represents an
important marker of procedure success and will have a signif-
icant impact on subsequent patient outcomes (7). In the
present registry, valvular function at the end of the viv-TAVI
procedure was excellent with respect to valve competence. In
Table 5. Procedural and In-Hospital Complications and Deaths (N  47)
Procedural complications 9 (19%)
Vascular access complications 6 (13%)
Bail-out implantation of 2nd TAVI prosthesis 2 (4%)
Need for mechanical resuscitation 2 (4%)
Refractory cardiac output failure 1 (2%)
Stroke 0
Conversion to open surgery 0
Valve embolization 0
Procedural death 1 (2%)
Days on the intensive care unit 2 (1–28)
Days in-hospital 8 (3–28)
Additional in-hospital complications 16 (34%)
Renal failure requiring dialysis 4 (9%)
Arrhythmias 3 (6%)
New pacemaker implantation 5 (11%)
Cardiac complications 3 (6%)
Infections/septic complications 3 (6%)
Bleeding requiring re-thoracotomy 1 (2%)
In-hospital deaths (including proc. deaths) 8 (17%)
NYHA functional class at discharge
I 12 (26%)
II 25 (53%)
III 1 (2%)
IV 0
Values are n (%) or median (range).
proc. procedural; other abbreviations as in Table 1.
Table 6. Nonsurvivors Versus Survivors
Nonsurvivors
(n  8)
Survivors
(n  39) p Value
Age, yrs 82.2 4.6 79.9 7.5 0.422
Males 6 (75%) 21 (54%) 0.525
Log EuroSCORE, % 56.6 22.4 30.5 14.2 0.001
Known CAD 6 (75%) 22 (56%) 0.031
Previous PCI 3 (38%) 5 (13%) 0.085
Previous CABG 2 (25%) 14 (36%) 0.697
Diabetes 3 (38%) 10 (26%) 0.673
Chronic renal failure 8 (100%) 20 (51%) 0.018
Left ventricular ejection fraction, % 45 13 53 12 0.083
Transapical viv-TAVI 5 (63%) 17 (44%) 0.446
Values are mean SD or n (%).Log logistic; other abbreviations as in Tables 1 and 3.
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1225only a single patient was moderate regurgitation observed,
without any case of severe aortic regurgitation. This is very
similar to the previous reports from Webb et al. (11) and
Kempfert et al. (12) who observed none or only mild regurgi-
tation in all of their patients after viv-TAVI. It should,
however, be noted that severe regurgitation was observed in 2
of the 47 (4%) patients during the procedure, necessitating
bail-out implantation of a second TAVI device during the
same procedure (“valve-in-valve-in-valve”). In 1 case, this was
due to central leakage after implantation of a balloon-
expandable Edwards Sapien valve, presumably reflecting mal-
function of the valve leaflets (24). In the second case, severe
paravalvular regurgitation was observed after too low implan-
tation of a Medtronic CoreValve prosthesis, necessitating
implantation of a second Medtronic CoreValve prosthesis.
The mean transvalvular gradients in the present series were
somewhat higher than previously observed after TAVI for
native aortic valve stenosis (25–27). This observation is, how-
ever, similar to that of previous viv-TAVI series (11). In our
series, the mean transvalvular gradient was 17  10 mm Hg,
but 44% of patients, in fact, had a mean transvalvular gradient
20 mm Hg after viv-TAVI. As compared with native aortic
valve TAVI, the higher post-procedural gradients are some-
what expected, given that the TAVI valve prosthesis is not
completely expanded but rather constrained within the smaller
Figure 5. Improvement in Functional Status After Viv-TAVI
NYHA  New York Heart Association; other abbreviations as in Figure 1.surgical bioprosthesis and may thus have higher transvalvulargradients and lower effective orifice areas than when relatively
fully expanded in a native aortic annulus (7). Our analysis
highlights that the size of the originally implanted surgical
bioprosthesis plays the most important role for prediction of
post-procedural transvalvular gradients. Smaller surgical bio-
prostheses of 23 mm labeled size tend to show higher
gradients after viv-TAVI than larger (25 mm) bioprostheses.
Furthermore, the design of the surgical bioprostheses may
affect transvalvular gradients after viv-TAVI. Most interest-
ingly, post-interventional gradients for specific types of surgical
bioprostheses were not predictable and varied between indi-
vidual patients. A trend toward lower gradients for Medtronic
CoreValve viv-TAVI procedures in small, 21-mm bioprosthe-
ses compared with Edwards Sapien valves was seen, but has to
be confirmed in the future.
The finding of elevated transvalvular gradients after viv-
TAVI may raise concerns with respect to long-term durability
of the viv-TAVI valve and therefore mandates close echocar-
diographic follow-up to detect early signs of deterioration of
valve function during further course. Nonetheless, these gradi-
ents should be viewed in lieu of the fact that most of these patients
had prohibitively high risk for redo aortic surgery and are much
lower than those observed among patients undergoing palliative
aortic valve balloon valvuloplasty for stenotic aortic bioprostheses,
a procedure that may not even be applicable for regurgitant
bioprosthetic valves, which constitutes a majority of the patients
with bioprosthetic valvular dysfunction.
There is ongoing debate with regard to the best-suited valve
prosthesis for viv-TAVI out of the currently available devices.
As in our series, the balloon-expandable Edwards Sapien valve
Figure 6. Kaplan-Meier Survival Curve of Patients Undergoing Viv-TAVIAbbreviations as in Figure 1.
A
f
t
(
h
S
m
i
d
n
p
(
o
t
t
a
T
p
a
a
i
h
f
i
e
h
w
S
a
m
f
t
a
a
a
s
v
c
i
m
p
n
a
c
s
v
g
a
p
p
v
b
p
n
p
a
t
t
e
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 1 1 , 2 0 1 1
N O V E M B E R 2 0 1 1 : 1 2 1 8 – 2 7
Eggebrecht et al.
Valve-in-Valve TAVI
1226has been used in most of the published viv series and case
reports so far (11,12,14). It is speculated that this prosthesis
may be better suited for this particular indication because of
facilitated positioning and intra-annular implantation proper-
ties (12). Implantation of the Medtronic CoreValve prosthesis
may be more demanding, and adjustment of prosthesis posi-
tion during deployment may be hampered because of increased
friction forces within the (metallic) ring of the surgical bio-
prosthesis. This may ultimately result in a noncorrectable too
low position of the valve inside the surgical bioprosthesis, with
subsequent severe paravalvular regurgitation, as occurred in a
patient in our present series. Often, the surgical bioprosthesis
offers a good landing zone for the Edwards Sapien valve (7).
lignment of the x-ray image with a perpendicular view allows
or very precise positioning within the surgical bioprosthesis. In
he presence of a degenerated stentless bioprosthetic heart valve
e.g., Elan valve, Vascutek, Inchinnan, United Kingdom),
owever, a rigid sewing ring for anchoring of the Edwards
apien valve is missing, and a Medtronic CoreValve prosthesis
ay theoretically be preferable because of more secure anchor-
ng of the prosthesis. Clearly, more information is needed to
etermine the best valve prosthesis for this indication.
Approximately 7% to 40% of patients undergoing TAVI for
ative aortic valve stenosis require implantation of a new
acemaker after the procedure for new-onset atrioventricular
AV) block (28,29). The rate of new pacemaker implantation
f 11% in the present series was not prohibitive, but was higher
han in previous series of patients undergoing viv-TAVI. In
he series of Webb et al. (11) and Kempfert et al. (12), not even
single patient of the total of 21 patients undergoing viv-
AVI for degenerated aortic bioprosthesis required new im-
lantation of a cardiac pacemaker after the procedure. The
uthors hypothesized that the rigid bioprosthetic sewing ring
nd valve frame protect the septal conduction tissues from
njury at the time of TAVI (7,11). The present study may,
owever, suggest that the type of the valve device that it is used
or viv-TAVI may influence the need for new pacemaker
mplantation after the procedure. The use of the self-
xpandable Medtronic CoreValve system was associated with a
igher rate (33%) of new pacemaker implantation as compared
ith the implantation of the balloon-expandable Edwards
apien valve (6%, p  NS), as was also observed previously
fter native-valve TAVI (29,30). The low rate of new pace-
aker implantation observed by Webb et al. (11) and Kemp-
ert et al. (12) may therefore simply reflect the exclusive use of
he balloon-expandable Edwards valve in their series. Patients
fter viv-TAVI using the Medtronic CoreValve device, but
lso the Edwards valve, should thus be carefully monitored for
new atrioventricular block after the procedure, following the
ame recommendations as for native-valve TAVI.
Stroke is an inherent risk of TAVI for native calcified aortic
alve stenosis. Previous studies have estimated the rate of
linically apparent stroke between 1% and 10%, whereas the
ncidence of clinically silent cerebral embolism during TAVIay even be much higher (16,31). In our series as well as in
revious viv-TAVI series, the stroke rate was zero in a total
ow of 76 patients (12–14). Although we are unable to provide
ny mechanistic insight in to this favorably low rate of
erebrovascular complications based on our data, we can
peculate some possible reasons for this in patients undergoing
iv-TAVI. Degenerated surgical bioprostheses often are regur-
itant and less calcified than native aortic valves, which are
lmost always stenotic and heavily calcified, particularly as most
atients presenting for TAVI are significantly older. Thus,
atients with bioprosthetic aortic valve dysfunction undergoing
iv-TAVI require not only lower rates of pre-dilation with a
alloon, but also less forceful dilation at lower atmospheric
ressures and less aggressive manipulation than patients with
ative aortic valve dysfunction undergoing TAVI. As such,
otentially a lower risk of periprocedural embolism may be
nticipated. Future research using continuous intraprocedural
ranscranial Doppler may help to provide more insights into
he differences in the embolic risk between TAVI for degen-
rated surgical bioprostheses and native aortic valve stenosis.
Clinical implications. Our multicenter registry confirms the
findings of previous single-center experiences suggesting that
transcatheter aortic valve implantation may be a promising
alternative to redo surgery for degenerated surgically implanted
tissue valves, particularly when the risk of surgery is high or
prohibitive. The high, reproducible procedural success rate of
viv-TAVI in the present registry, as well as in previous series,
lends some additional credibility to this affirmation. Post-
procedural complications and deaths appear to be high, but in
fact, they are still acceptable when the predicted rates using the
euroSCORE are considered. Additionally, the higher propor-
tion of deaths related to sepsis may have further implications
for improving outcomes of patients undergoing viv-TAVI.
Development of appropriate and perhaps more aggressive strate-
gies for post-operative patient management may help to reduce
the incidence of periprocedural sepsis. Expected technical im-
provements of TAVI valves and delivery systems in the next 5 to
10 years and a growing understanding of optimal periprocedural
management of these patients is likely to have a significant impact
on outcomes of patients undergoing viv-TAVI. Finally, the
possibility that not all currently available TAVI devices may be
appropriate for viv-TAVI needs future evaluation.
Strengths and limitations. So far, the published literature on
patients undergoing viv-TAVI is limited to reports of single cases
or selected patient series. In contrast, our report represents by far
the largest reported current experience with viv-TAVI for failed
aortic bioprostheses. Our study should, however, be viewed in the
light of its limitations. Most important, our analysis is a retrospec-
tive analysis of viv-TAVI cases. We were able to collect informa-
tion on all patients during hospitalization and up to 30 days after
the procedure. Data beyond this point were not available for
all patients. Prospective, multicenter, large-scale registries (and
perhaps randomized clinical trials comparing TAVI with surgery)
are required to evaluate the short- and long-term safety and
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1227efficacy of TAVI for this special indication in comparison with
redo surgical valve replacement.
Conclusions
Our data indicate that viv-TAVI can be performed with high
technical success rates and excellent post-procedural valvular func-
tion. However, in these elderly high-risk patients with multiple
comorbidities, viv-TAVI was associated with 17% mortality that
was related to septic complications in 3 of a total of 8 deaths. The
already existing efforts at improving technology along with better
post-operative management are likely to improve the future
outcomes of viv-TAVI in this high-risk patient population.
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